Microbial CMO Wacker buys Dutch biotech plant

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Arindam Ghosh)
(Image: Getty/Arindam Ghosh)
Wacker Chemie has acquired SynCo Bio’s site for manufacturing biopharmaceuticals, live microbial products, and vaccines, as well as its associated business, including more than 100 employees.

SynCo Bio Luxembourg S.à.r.l operates two fermentation lines – for the manufacture of microbial-derived biopharmaceuticals for clinical testing and the commercial market – with capacities of 1,500 and 270 L.

According to the Munich-based contract manufacturing organization (CMO) Wacker, the Dutch site also features a line of single-use fermenters and a fill/finish facility, which meet good manufacturing practice (GMP) quality standards and European Medicines Agency (EMA) and US Food and Drug Administration (FDA) approval.

This strategic acquisition is a key step for our ongoing expansion in the high-growth biopharmaceuticals market,”​ explained Auguste Willems of Wacker’s executive board.

“The new plant will enable us to satisfy robust market demand today and in the coming years – and to strengthen our position as a leading contract manufacturer of microbial-derived biopharmaceutical proteins,” ​he said in the press release.

Wacker is a contract manufacturer of biopharmaceutical proteins based on microbial systems. The company provides analytical services and process development for the manufacture of clinical test samples and pharmaceutical actives for the commercial market.

Under the agreement – terms of which were not disclosed – Wacker will retain all 110 SynCo employees.

Wacker is not providing any additional comment at this time.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us


View more